6657 Hwa An Announces Technology and Patent Rights Transfer to Subsidiary Yuan Hwa Smart Medicine

Release Date: July 9, 2026 Statement Date: July 8, 2026 Statement Time: 17:51:39 Company Code: 6657 Company Name: Hwa An Subject: Announcement of Technology and Patent Application Rights Assignment Agreement with Subsidiary Yuan Hwa Smart Medicine Inc. Applicable Clause: Item 10 Event Date: July 8, 2026

1. Event Date: 07/08/2026 2. Contract Counterparty: Yuan Hwa Smart Medicine Inc. 3. Relationship with Company: 100% owned subsidiary of the Company 4. Contract Effective Date (or Termination Date): 07/08/2026 5. Main Content: Hwa An and its subsidiary Yuan Hwa Smart Medicine Inc. have entered into a technology and patent application rights assignment agreement. Hwa An will transfer its proprietary technology, trade secrets, know-how, and patent application rights related to the 'USE OF BREMELANOTIDE FOR THE TREATMENT OF VITILIGO' to Yuan Hwa Smart Medicine. In return, Yuan Hwa Smart Medicine will issue 4,500,000 ordinary shares, each with a par value of NT$10, to Hwa An as partial consideration. The parties may further agree in writing on milestone-based bonuses as additional payments and their triggering conditions. 6. Restrictive Clauses: As stipulated in the contract 7. Commitment Matters: None 8. Other Important Agreements: None 9. Impact on Company's Financial and Business Operations: The proprietary technology, trade secrets, know-how, and patent application rights related to vitiligo treatment hold significant market potential. Hwa An expects this assignment to have a positive impact on its future financial and business performance. 10. Specific Purpose: Based on the overall operational planning of the Hwa An Group 11. Other Matters to be Disclosed: New drug development involves long timelines, high investment costs, and no guarantee of success, which may pose risks to investors. Investors should make careful judgments and invest prudently.